调研速递|博济医药接受多家投资者调研，聚焦创新药研发与业绩影响等要点

Core Insights - The company held an investor meeting on September 19, discussing its ongoing projects and financial performance [1][2] - The "Semaglutide Injection" project with Novartis is currently in the Phase III clinical trial follow-up stage, which is expected to positively impact future operating performance [1] - The company focuses on providing CRO services primarily for innovative drugs across various therapeutic areas [1] Group 1: Project Development - The company is developing several innovative drugs, including a traditional Chinese medicine for chronic heart failure and a small molecule new drug for high uric acid levels [2] - Currently, there are no self-developed projects in the oncology field, but the company provides clinical research services for multiple oncology drugs [2] - The timeline for research and development is influenced by project progress and the sponsor's investment [2] Group 2: Financial Management - The company emphasizes improving operational quality as the core of its market value management [2] - Idle cash is primarily invested in low-risk, high-liquidity financial products rather than high-risk securities or derivatives [2] - For the first half of 2025, the company's R&D investment was approximately 23.2 million, accounting for about 6% of revenue, which is higher than the net profit for the same period [2]